BioCentury
ARTICLE | Company News

Liquidia, Lq3 dental, drug delivery news

September 15, 2014 7:00 AM UTC

Liquidia spun out Lq3 to develop therapies for oral health conditions using Liquidia's Particle Replication in Non-Wetting Templates (PRINT) drug delivery technology. Lq3 has an undisclosed oral health product in preclinical testing. Lq3's CEO is Kyle Chenet, formerly VP of corporate development at Liquidia and Liquidia's Envisia Therapeutics Inc. spinout. Liquidia will continue to develop PRINT-based vaccines and inhaled therapeutics. ...